If you want to understand a biotech franchise, don't read the marketing — read its patents in order. For Genentech's anti-VEGF eye program, that record tells a clear, layered story, and it starts with one target: VEGF, the protein behind the leaky vessels that cause vision loss.

Layer one is the molecule. An antibody is a large protein engineered to grab one target and hold on. But a first-generation antibody is rarely the final product — it gets refined.

“The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis.”— U.S. Patent No. 10,899,828 source

Layer two is optimization, and this is where Genentech's US10899828B2 sits: optimized variants of anti-VEGF antibodies. In plain terms, the company re-engineered the protein to behave better — bind tighter, last longer, or tolerate the harsh environment of the eye — and patented those specific variants. The companion publication US20210115124A1 stakes out the same optimized-variant ground.

Layer three is the part readers overlook: the formulation. Publication US20210363231A1 covers optimized antibody compositions for treating ocular disorders — the actual injectable preparation. A molecule you can't formulate into a safe, stable eye injection isn't a product.

Why does this layering matter to a reader trying to value the franchise? Because protection isn't a single date on a single patent. The molecule, the variants, and the formulation can expire at different times, and a competitor has to clear all the live ones. That is what turns a drug into a moat.

The short version is that Genentech's anti-VEGF program reads, in the patent record, like a building rather than a brick. Each floor — molecule, variant, formulation — is separately deeded. Understanding that structure is the difference between thinking a franchise is about to fall and seeing why it tends to hold.